Australia's CSL half-year profit up despite weak flu vaccine sales
By Christine Chen (Reuters) -Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were ...
Heating up down under: Chinese buyers are buying more expensive properties in Australia
In the financial year that ended in June, people from China were the largest foreign investors in Australian residential ...
spectator.com.au1d
Australian company insolvencies
ASIC released their latest insolvency statistics earlier this week and the results are concerning. A company becomes ...
Australian consumers stay cautious in February, survey says
Australian consumer sentiment remained in the doldrums in February, a survey showed on Tuesday, failing to benefit from ...
Australian companies' high valuations face a crucial earnings test
Corporate Australia kicks off its half-year earnings in full swing next week, and while modest growth is expected, traders ...
Australian working-class households plunged into financial stress
A historic cut to living standards has occurred, mostly since Labor scraped into office in May 2022, fuelling a political ...
Sydney Morning Herald11d
How super funds are spending your money
Add articles to your saved list and come back to them any time. Australian super funds’ expenses swelled to almost $13 billion last financial year, including a $500 million splurge on an ...